The estimated Net Worth of Jonathan Jay Mazelsky is at least $54.1 Million dollars as of 5 August 2024. Mr. Mazelsky owns over 384 units of Idexx Laboratories stock worth over $40,153,275 and over the last 12 years he sold IDXX stock worth over $6,494,488. In addition, he makes $7,419,340 as President, Chief Executive Officer und Director at Idexx Laboratories.
Jonathan has made over 45 trades of the Idexx Laboratories stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 384 units of IDXX stock worth $188,260 on 5 August 2024.
The largest trade he's ever made was exercising 25,000 units of Idexx Laboratories stock on 17 February 2021 worth over $1,300,000. On average, Jonathan trades about 3,120 units every 60 days since 2012. As of 5 August 2024 he still owns at least 81,902 units of Idexx Laboratories stock.
You can see the complete history of Mr. Mazelsky stock trades at the bottom of the page.
Jonathan Mazelsky serves as President, Chief Executive Officer, Director of the Company. He was Executive Vice President of the IDEXX Laboratories, Inc. Mr. Mazelsky has been an Executive Vice President since joining us in August 2012. He oversees our North American Companion Animal Group Commercial Organization, and our IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business. Previously, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.
As the President, Chief Executive Officer und Director of Idexx Laboratories, the total compensation of Jonathan Mazelsky at Idexx Laboratories is $7,419,340. There are 1 executives at Idexx Laboratories getting paid more, with Jonathan Ayers having the highest compensation of $8,309,800.
Jonathan Mazelsky is 59, he's been the President, Chief Executive Officer und Director of Idexx Laboratories since 2019. There are 7 older and 16 younger executives at Idexx Laboratories. The oldest executive at Idexx Laboratories, Inc. is M. Anne Szostak, 69, who is the Independent Director.
Jonathan's mailing address filed with the SEC is ONE IDEXX DRIVE, , WESTBROOK, ME, 04092.
Over the last 22 years, insiders at Idexx Laboratories have traded over $238,711,289 worth of Idexx Laboratories stock and bought 24,695 units worth $3,109,424 . The most active insiders traders include Stuart Essig, Johnny D Powers und Jonathan W Ayers. On average, Idexx Laboratories executives and independent directors trade stock every 9 days with the average trade being worth of $4,641,291. The most recent stock trade was executed by M Anne Szostak on 5 September 2024, trading 500 units of IDXX stock currently worth $234,685.
idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an
Idexx Laboratories executives and other stock owners filed with the SEC include: